Jim Chanos has a way to profit on the drug overpricing backlash and still hates Tesla

The S&P is trying to prune its losses for the week, but some analysts warn that going long too soon could prove costly. For those not going long, Jim Chanos is offering up short ideas — among pharma stocks, in particular.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.